[go: up one dir, main page]

EP0649474A4 - Depistage de la maladie d'alzheimer non familiale. - Google Patents

Depistage de la maladie d'alzheimer non familiale.

Info

Publication number
EP0649474A4
EP0649474A4 EP93916630A EP93916630A EP0649474A4 EP 0649474 A4 EP0649474 A4 EP 0649474A4 EP 93916630 A EP93916630 A EP 93916630A EP 93916630 A EP93916630 A EP 93916630A EP 0649474 A4 EP0649474 A4 EP 0649474A4
Authority
EP
European Patent Office
Prior art keywords
assaying
platelets
response
thrombin
carboxyfluorescein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93916630A
Other languages
German (de)
English (en)
Other versions
EP0649474A1 (fr
Inventor
Elizabeth R Simons
Theresa A Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of EP0649474A1 publication Critical patent/EP0649474A1/fr
Publication of EP0649474A4 publication Critical patent/EP0649474A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Definitions

  • AD Alzheimer's disease
  • ⁇ APP a neurodegenerative disease of the central nervous system
  • ⁇ APP a neurodegenerative disease of the central nervous system
  • a first is Familial Alzheimer' s Disease (FAD) which is genetically linked, generally exhibits an early onset and may be caused by a faulty gene for the Alzheimer's precursor protein, ⁇ APP, on chromosome 21 leading to an altered ⁇ APP sequence.
  • FAD Familial Alzheimer' s Disease
  • AD Alzheimer's disease
  • ⁇ APP amyloid precursor protein
  • Platelets are one of several cellular components of blood and when appropriately stimulated, exhibit a response that includes, inter alia, a change in the membrane potential of the platelet, changes in the intra-cellular Ca + + and a secretion or release of granules and the granules' contents.
  • platelet activation in response to physiological stimuli such as ⁇ -thrombin (less than 4.5nM) has been extensively studied.
  • Cf. for example, Davies et al, (1987) Analyt.
  • a principal object of the present invention is to provide an assay for Alzheimer' s disease in live patients.
  • the invention herein described and claimed generally then is a method of assaying for non-familial Alzheimer' s disease in a live patient, comprising the steps of collecting platelets from the blood of said patient and stimulating those platelets with a physiological agonist, typically ⁇ -thrombin, in order to invoke a characteristic acidification response in the platelet cytoplasm.
  • a physiological agonist typically ⁇ -thrombin
  • Other known agonists include, but are not limited to, collagen, adenosine disphosphate, epinephrin, ristocetin and the like.
  • the extent of that response immediately following stimulation is determined, preferably with a pH- sensitive probe such as fluorescent material which can be emplaced within the platelet cytoplasm.
  • That measured extent of response is then compared with the corresponding stimulated acidification response in platelets from normal individuals, i.e- those apparently not suffering from non-familial Alzheimer's disease.
  • Stimulation of human platelets by thrombin is known to be accompanied by, inter alia, a rapid thrombin-dose-dependent cytoplasmic acidification or change in the pH;., within a few seconds (e.g. 3 or 4 sec.), followed by a cytoplasmic alkalinization that maximizes quickly.
  • the extent of cytoplasmic acidification can then be determined using any of a number of pH sensitive techniques such as with fluorescent probes including 6-carboxyfluorescein (hereinafter 6-CF), 2 * ,7'-bis(carboxyethyl)-5(6)-carboxyfluorescein (hereinafter BCECF) and the like.
  • 6-CF 6-carboxyfluorescein
  • BCECF 2 * ,7'-bis(carboxyethyl)-5(6)-carboxyfluorescein
  • the esters of these fluorescein derivatives are non-fluorescent and, in this form, pass freely across the platelet plasma membrane. Inside the cell, the ester group is believed to be cleaved by nonspecific cytoplasmic esterases, generating an in situ pH-sensitive fluorescein probe.
  • BCECF is preferred as a probe over 6-CF inasmuch as the former has a higher pK (6.9) and is pH sensitive to 7.8 or 7.9.
  • Thrombin-induced activation of platelets was measured by signal transduction and degranulation for younger individuals (hereinafter Control) and age-matched older normal (AM) and Alzheimer's diseased patients (AD) as identified by the criteria developed by the Alzheimer's Disease and Related Dementia Association in conjunction with the National Institute of Aging (McKhann et al (1984) Neural. 34, 939). Neutrophils isolated from the same blood samples were used as controls.
  • the neutrophils from all three groups exhibited identical responses (depolarization and oxidative burst) to the chemotactic peptide formyl methionine leucine phenylalanine, indicating that the platelet difference in AD patients are not attributable to any artifact in the patient's blood per se. Additionally, the platelet resting parameters, pH.-, ⁇ and [Ca ++ ] rejting , in the three groups were not significantly different. However, the maximum change in cytoplasmic thrombin-induced acidification, usually reached within the first few seconds (e.g. ca.
  • Sepharose 2B a sugar polymer used in column chromatography and serving as a selective filter that permits the larger particles to pass through while retaining the smaller particles
  • the fluorescent probes such as 2',7'-bis (carboxyethyl)- 5(6)- carboxyfluorescein-acetoxymethyl ester (hereinafter BCECF-AM) and 5(6)-carboxyfluorescein diacetate (6-CF), as well as the ionophore nigericin, were obtained from Molecular Probes, Inc. of Eugene, Oregon.
  • HEPES 4-(2 hydroxyethyl)-l-piperazine ethane-sulfonic acid
  • K + -Hepes buffer 0.140 M KC1, 0.0038 M HEPES, 0.0055 M D-glucose, 0.0033 M monobasic sodium phosphate, 0.001 M MgCl 2 -6H 2 0, 0.15U/liter apyrase, pH 6.6 - 7.6.
  • PLATELETS Fresh whole blood from volunteers was anticoagulated with 0.38% sodium citrate. Platelet-enriched plasma was obtained by centrifugation, and the platelets separated by passage over a Sepharose 2B column equilibrated with a Hepes buffer (pH 7.4) as described in Home et al (1981) Eur. J. Biochem. 120, 295-302. EXAMPLE I.
  • the resuspended pellets were then diluted to a final concentration of about 30xl0 6 platelets/ml with either Hepes buffer, pH 7.4, for thrombin response measurements, or K + -Hepes buffer at varying pHs, immediately before use, for calibration curves.
  • Hepes buffer pH 7.4, for thrombin response measurements, or K + -Hepes buffer at varying pHs, immediately before use, for calibration curves.
  • ⁇ -thrombin 0.0025-0.05 U/ml, 0.45-9 nM
  • Intracellular pH was determined from a calibration curve prepared using the same ratio procedure as described by Thomas et al, (1979) Biochemistry 18, 2210-2218, correlating the difference at set pH values (pH 6.6 to 7.6) with ratios obtained when cells, incubated in K + - Hepes buffer are measured before and after the addition of nigericin (Davies et al, (1987) Analyt. Biochem. 167, 118-123).
  • a relative rate of cytoplasmic pH change can also be determined by measuring the initial slope of the thrombin induced fluorescence change (cm/min), divided by the initial F 450 (i.e. initial pH-insensitive ) value for the probe (Davies et al (1990) J. Biol. Chem. 265, 11522).
  • the rate and extent of cytoplasmic acidification for the three groups for different doses of thrombin is given in the following Table in which the rate of cytoplasmic acidification was ⁇ pH/ ⁇ t in reciprocal seconds, and the extent of acidification was measured as ⁇ pH.
  • Example II Intracellular pH was determined from a calibration curve prepared as described in Example III, and the data substantiated the data given in Table I for controls. EXAMPLE III. The method described in Example I was repeated, however, 2 ⁇ M nigericin, instead of thrombin was added to the platelets in order to prepare a pH calibration curve, and platelets were diluted in K + -Hepes at varying pH (6.6 to 7.6) instead of normal Hepes. The change in ratio was calculated as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP93916630A 1992-07-09 1993-06-18 Depistage de la maladie d'alzheimer non familiale. Withdrawn EP0649474A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91116192A 1992-07-09 1992-07-09
US911161 1992-07-09
PCT/US1993/005881 WO1994001579A1 (fr) 1992-07-09 1993-06-18 Depistage de la maladie d'alzheimer non familiale

Publications (2)

Publication Number Publication Date
EP0649474A1 EP0649474A1 (fr) 1995-04-26
EP0649474A4 true EP0649474A4 (fr) 1996-04-03

Family

ID=25429832

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93916630A Withdrawn EP0649474A4 (fr) 1992-07-09 1993-06-18 Depistage de la maladie d'alzheimer non familiale.

Country Status (2)

Country Link
EP (1) EP0649474A4 (fr)
WO (1) WO1994001579A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO9401579A1 *
T.A. DAVIES ET AL.: "NON-AGE RELATED DIFFERENCES IN THROMBIN RESPONSES BY PLATELETS FROM MALE PATIENTS WITH ADVANCED ALZHEIMER'S DISEASE.", MOLECULAR BIOLOGY OF THE CELL, vol. 4, no. SUP, - 11 December 1993 (1993-12-11), NEW ORLEANS LA USA, pages 124A *
T.A. DAVIES ET AL.: "Simultaneous flow cytometric measurements of thrombin-induced cytosolic pH and Ca-ion fluxes in human platelets", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 20, - 1 July 1990 (1990-07-01), WASHINGTON DC USA, pages 11522 - 11526, XP000561928 *

Also Published As

Publication number Publication date
WO1994001579A1 (fr) 1994-01-20
EP0649474A1 (fr) 1995-04-26

Similar Documents

Publication Publication Date Title
Nelson et al. Characterization of protein F1 (47 kDa, 4.5 pI): a kinase C substrate directly related to neural plasticity
Hajimohammadreza et al. Platelet and erythrocyte membrane changes in Alzheimer's disease
Di Donato et al. The complex clinical and genetic classification of inherited ataxias. II. Autosomal recessive ataxias
US6607919B1 (en) Method and assay kit for evaluation of the oxidative modification of protein-containing substances
JPH10506990A (ja) アルツハイマー病に関する細胞試験と診断指数
JPH09500202A (ja) アルツハイマー病の細胞試験
Wolozin et al. Olfactory neuroblasts from Alzheimer donors: studies on APP processing and cell regulation
Faucher et al. Relationship between pH, sodium, and shape changes in chemotactic‐factor‐stimulated human neutrophils
Pettegrew et al. Membrane studies in Huntington's disease: Steady‐state fluorescence studies of intact erythrocytes
Mazeaud et al. Biochemical and functional alterations associated with hypercholesterolemia in platelets from hypertensive patients
Nanda et al. Assessment of the contribution of the cytochrome b moiety of the NADPH oxidase to the transmembrane H+ conductance of leukocytes.
Restrepo et al. Olfactory neurons exhibit heterogeneity in depolarization-induced calcium changes
Ortiz‐Carranza et al. Activation of bovine neutrophils by Pasteurella haemolytica leukotoxin is calcium dependent
Sang et al. Alterations of platelet membrane microviscosity in essential hypertension
McNicol et al. The empty sack syndrome: a platelet storage pool deficiency associated with empty dense granules
Bothwell et al. Platelet intracellular calcium in patients with recurrent affective disorders
EP0649474A1 (fr) Depistage de la maladie d'alzheimer non familiale
Stibler et al. Changes in (Na++ K+) ATPase activity and the composition of surface carbohydrates in erythrocyte membranes in alcoholics
Heemskerk et al. Presynaptic mechanism of action of 4‐aminopyridine: Changes in intracellular free Ca2+ concentration and its relationship to B‐50 (GAP‐43) phosphorylation
Kelly et al. Dissociation of striatal GTPase and dopamine release responses to muscarinic cholinergic agonists in F344 rats: influence of age and dietary manipulation
US6030768A (en) Analysis of conformational changes in band 3 protein as a method for diagnosing Alzheimer's disease
EP1275962A1 (fr) Procédé de détection de substances oxydantes ou de radicaux libres dans la salive et kit correspondant
Preston et al. Isolation and characterization of paramecium mutants defective in their response to magnesium.
Wesemann et al. Modulation of serotonin binding in rat brain by membrane fluidity
Joseph et al. Cytosolic ionized calcium homeostasis in platelets: an abnormal sensitivity to PAF‐activation in migraine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19941219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB

A4 Supplementary search report drawn up and despatched

Effective date: 19960219

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): DE FR GB

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19960604